Key result
Systemic chemotherapy for breast cancer is associated with cardiotoxicity, though clinical trials often exclude women with baseline cardiovascular compromise.
Population
Women with breast cancer receiving systemic chemotherapy, including those with baseline cardiovascular…
Design
Review
Authors
Loading...
Calls for inclusive cardio-oncology trials; leaves open cardiotoxicity risks in patients with baseline CV compromise.
This review highlights the epidemiology, mechanisms, and management of chemotherapy-induced cardiotoxicity in breast cancer, emphasizing the need to include women with preexisting cardiac conditions in future clinical trials.
Rozner et al. (2018) conducted a review in Breast cancer and cardiotoxicity. Systemic chemotherapy was evaluated. Systemic chemotherapy for breast cancer is associated with cardiotoxicity, though clinical trials often exclude women with baseline cardiovascular compromise.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: